Castle Biosciences (CSTL) Other Non-Current Assets (2018 - 2026)

Castle Biosciences has disclosed Other Non-Current Assets across 9 years of filings, most recently posting $4.3 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $4.3 million, up 237.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (up 237.91% YoY), and the FY2025 annual result was $3.8 million, up 206.92% from the prior year.
• Other Non-Current Assets came in at $4.3 million for Q1 2026 at Castle Biosciences, up from $3.8 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $4.3 million in Q1 2026 to a low of $792000.0 in Q1 2023.
• The 5-year median for Other Non-Current Assets is $1.3 million (2025), against an average of $1.8 million.
• Across the five-year window, Other Non-Current Assets slumped 70.66% in 2023 and surged 237.91% in 2026, its largest moves.
• Castle Biosciences' Other Non-Current Assets stood at $1.1 million in 2022, then climbed by 29.73% to $1.4 million in 2023, then declined by 14.72% to $1.2 million in 2024, then surged by 206.92% to $3.8 million in 2025, then climbed by 13.5% to $4.3 million in 2026.
• The last three Other Non-Current Assets figures came in at $4.3 million (Q1 2026), $3.8 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.